Skip to main content
. Author manuscript; available in PMC: 2023 Feb 17.
Published in final edited form as: Oncogene. 2018 Jan 31;37(16):2181–2196. doi: 10.1038/s41388-017-0080-4

Figure 2. ES and leukemia cell lines are more sensitive to clofarabine and cladribine.

Figure 2.

Cell viability was evaluated by WST-1 or MTT assay following 48 h treatment with clofarabine (A) and cladribine (B). The IC50 values were determined by nonlinear regression analysis using GraphPad Prism version 6.0h software. The average IC50 concentrations of clofarabine were 0.44 ± 0.44 for ES, 0.18 ± 0.01 for leukemia and 13.73 ± 11.54 for non-ES cell lines. The average IC50 concentrations of cladribine were 1.09 ± 1.85 for ES, 0.34 ± 0.03 for leukemia and 20.05 ± 13.16 for non-ES cell lines. The average IC50 concentration for non-ES cell lines was calculated using the highest concentrations tested (either 10 or 30 μmol/L) for resistant cell lines. Values are presented as the mean ± SD of three technical replicates.